This article has Open Peer Review reports available.
Why do family doctors prescribe potentially inappropriate medication to elderly patients?
© The Author(s). 2016
Received: 13 October 2015
Accepted: 13 July 2016
Published: 22 July 2016
Based on changes in pharmacokinetics and –dynamics in elderly patients, there are potentially inappropriate medications (PIM) that should be avoided in patients aged ≥ 65 years. Current studies showed prescription rates of PIM between 22.5 and 28.4 % in the primary care setting. The evidence concerning reasons for PIM prescription by FPs is limited.
This mixed method study consisted of three research parts: 1) semi-standardized content analysis of patients’ records, 2) qualitative interviews with FPs using a) open questions and b) selected patient-specific case vignettes and 3) qualitative interviews with FPs’ medical assistants. The integration of qualitative interviews was used to explain the quantitative results (triangulation design). PIM were identified according to the German PRISCUS list. Descriptive and multivariate statistical analysis was done using SPSS 22.0. Qualitative content analysis of interviews was used to classify the content of the interviews for indicating pertinent categories. All data were pseudonymously recorded and analyzed.
Content analysis of 1846 patients’ records and interviews with 7 related FPs were conducted. Elderly patients [n = 1241, mean age: 76, females: 56.6 %] were characterized in average by 8.3 documented chronic diagnosis. 23.9 % of elderly patients received at least one PIM prescription. Sedatives/hypnotics were the most frequent prescribed PIM-drugs (13.7 %). Mental disorders, gender and number of long-term medication were detected as predictors for the probability of a PIM prescription. Common reported reasons for PIM prescription by FPs concerned limited knowledge regarding PIM, limited applicability of PIM lists in daily practice, lack of time, having no alternatives in medication, stronger patient-related factors than age that influence prescription, own bad experiences regarding changes of medication or refusal of following prescriptions of sedative/hypnotics.
It is essential to see FPs in a complex decision making situation with several influencing factors on their prescribing, including: patient-oriented prioritization, FPs’ experiences in daily practice, FPs’ knowledge regarding existing recommendations and their trust in it and organizational characteristics of FPs’ daily medical practice. These pros and cons of PIM prescription in elderly patients should be considered in FPs’ advanced training.
The discussion of challenges in medical care for elderly patients (65 years and older) is focused on multimorbidity and polypharmacy. Regarding age-related changes in pharmacokinetics and -dynamics, the elderly patients’ renal metabolism and clearance as well as first-pass effect in the liver are delayed in time. This causes different actions of drug in geriatric vs. younger patients because the pharmaceutical drugs remain longer in the metabolic system of the elderly .
Prescription of medical drugs in geriatric patients has to consider these effects. But mostly there is no evidence regarding effect of drugs in the elderly. Clinical trials for testing efficacy of drugs often exclude older patients based on an upper-age limit, comorbid disease, reduced life expectancy, physical or mental impairments or use of drugs aiming to minimize biases on outcomes of the study. But the results of efficacy studies that exclude older patients do rarely fit patients in daily medical practice [2, 3].
Common empirical data show higher hospital admission rates in elderly patients because of adverse drug reactions or drug-drug reactions [4–6]. Regarding this and the complexity of problems with medication for the elderly, expert groups in several countries have developed so called black lists of drugs for elderly patients, describing potentially inappropriate medication (PIM).
Due to different formalities and drug markets, country specific PIM lists are necessary . These country-specific lists include drugs that are associated with higher risks of intolerance, adverse drug reaction/events or drug-disease interactions in elderly patients [8–14].
In Germany the first black list ‘PRISCUS’ (PRerequISites for a new health Care model for elderly people with mUltiple morbiditieS) was consensually developed in 2010 by an expert group of geriatrics, pharmacologists and family practitioners. PRISCUS currently includes 83 drugs that should be avoided or prescribed at a lower dose in elderly patients. These recommendations are listed with expert statements offering alternatives. In case of unavoidability of PIM prescriptions, recommendations for drug monitoring are given .
Rates of PIM prescriptions range worldwide between 12 and 65 % depending on the setting and the used screening tool. A systematic review determined a median PIM prescription rate of 20.5 % (interquartile range 18.1 to 25.6 %) in the primary care setting between 1950 and 2011. The review included 19 studies of 11 different countries that examined PIM almost by Beers criteria . Current studies examining older patient samples (mean age > 80 years) showed prescription rates between 22.5 and 28.4 % in the primary care setting [17, 18].
Since these rates seem to be high, it would be useful to understand the prescribing of PIM by family practitioners (FP) to generate feasible and need-oriented solutions for improvement of medical care in the elderly. In this context, more evidence is needed regarding FPs’ knowledge of PIM as well as associated recommendations and their acceptance and implementation in daily practice.
There is evidence that polypharmacy increases the risk of PIM in elderly patients [6, 18, 19]. Furthermore, there are indications that FPs’ knowledge of prescribing for the elderly is partly insufficient (more frequently in older FPs) whereas they report a high self-rated confidence in prescribing . Reported main barriers for appropriate prescribing seem to be related to FPs’ lack of education regarding PIM, to organizational characteristics (i.e. lack of time, limited answer options on insurance formularies, communication difficulties with other doctors) and to patients (large number of medications, unknown medications, costs). These findings are based on two smaller studies using a validated survey instrument to examine FPs’ knowledge of prescribing for the elderly. Appropriateness was assessed by standardized case vignettes [20, 21].
to give an overview of rates of PIM prescription in our study sample of elderly multimorbid patients with polymedication in the outpatient primary care setting,
to explain influencing factors on prescription of PIM,
to examine knowledge and application of PRISCUS and
to understand FPs’ reasons for prescription of PIM.
Our study was coordinated at the Department of General Practice of the Technische Universität (TU) Dresden and took place from March 2013 to June 2014. The study was conducted in cooperation with the Department of Health Care Management and Public Health/Schumpeter School of Business and Economics at the University of Wuppertal.
semi-standardized content analysis of patients’ records regarding morbidity, drug prescriptions, admissions/referrals to specialist,
qualitative interviews with FPs that focused on challenges and barriers in daily medical care of patients with multimorbidity and polypharmacy using a) open questions to explore these issues in general and b) selected patient-specific case vignettes for each FP based on results of  regarding comparable topics (PIM: prescription of hypnotics; medication change; intersectoral cooperation with in- and out-patient specialists), and
qualitative interviews with their medical assistants to explore their point of view regarding organization-related barriers, challenges and room for improvement for medical care of patients with multimorbidity and polypharmacy .
Results of qualitative interviews with FP and their medical assistants were used to help explain the quantitative results (triangulation design ). More detailed information on our study design, setting and research instruments are already published elsewhere .
This publication focuses on results of subanalysis of research parts (1) and (2) regarding the prescription of PIM by FPs.
Inclusion of study participants
All 33 FPs from academic teaching practices of the Department of General Practice of TU Dresden situated in Dresden were invited for participation in the study. After confirmation of participation by the FPs, all chronic patients of each participating practice were invited for participation if they met following inclusion criteria: a) at least two parallel chronic diseases and b) two prescribed long-term medications at least 6 months before 2012. Furthermore, all medical assistants of the participating FPs were asked to participate in qualitative interviews.
Patients’ records  were analyzed from March 2013 to May 2014 by our project assistants at FPs’ practices using a semi-standardized entry mask in SPSS 22.0. Patient records of a randomized quarter of the year 2012 were retrospectively analyzed per patient, and information regarding morbidity, admissions/referrals to specialists and non-drug and drug prescriptions (including documented adverse events) were documented. Prescriptions by specialists were only included if FPs had documented them in the patient records based on the findings reports sent by the specialists or direct information by the patients.
Description of case vignettes regarding documented prescription of PIM
Documented chronic conditions of the case (ICD-10)
Documented acutediagnosis of the case (ICD-10)
Prescription of PIM per quarter: agents/amount (prescribed daily dosage)
Further agents for long-term treatment/same quarter
D25: Leiomyoma of uterus
F43: Reaction to severe stress, and adjustment disorders
Zolpidem/80 pellets (missing)
Candesartan, Carbamazepine, Doxepin, Gabapentin, Metoprolol, Metformin, Pravastatin
E22: Hyperfunction of pituitary gland
E78: Disorders of lipoprotein metabolism
G25: Other extrapyramidal and movement disorders
G47: Sleep disorders
G56: Mononeuropathies of upper limb
G58: Other mononeuropathies
I10: Essential (primary) hypertension
I65: Occlusion and stenosis of precerebral arteries
R55: Syncope and collapse
F13: Mental and behavioral disorders due to use of sedatives or hypnotics
Zopiclone/60 pellets (7.5 mg/day), Lorazepam/missing (2.5 mg/day)
Acetylsalicylic acid, Amlodipine, Calcitrol, Carvedilol, Cholecalciferol, Minoxidil, Mirtazapine, Pantoprazole, Torasemide, Valsartan
F34: Persistent mood [affective] disorders
F40: Phobic anxiety disorders G47: Sleep disorders
I10: Essential (primary) hypertension
N18: Chronic kidney disease
T88: Other complications of surgical and medical care, not elsewhere classified
J06: Acute upper respiratory infections of multiple and unspecified sites
Zolpidem/80 pellets (10 mg/day)
Beclomethasone, Bisoprolol, Cobalamin, Duloxetine, Hydrochlorothiazide, Lactulose, Levothyroxine, Metoclopramide, Omeprazole, Salbutamol, Tramadol,
E53: Deficiency of other B group vitamins
I35: Nonrheumatic aortic valve disorders I50: Heart failure
K29: Gastritis and duodenitis
M48: Other spondylopathies
Q61: Cystic kidney disease
R15: Faecal incontinence
R52: Pain, not elsewhere classified
Zolpidem/100 pellets (10 mg/day)
Hydrochlorothiazide, Naloxone, Nitrendipine, Pregabalin, Tilidine, Valsartan
E78: Disorders of lipoprotein metabolism and other lipidaemias
G47: Sleep disorders
H53: Visual disturbances
I10: Essential (primary) hypertension
I83: Varicose veins of lower extremities
M25: Other joint disorders, not elsewhere classified
M81: Osteoporosis without pathological fracture
N17: Acute renal failure
R26: Abnormalities of gait and mobility
Z93: Artificial opening status
C80: Malignant neoplasm, without specification of site
R07: Pain in throat and chest
Zopiclone/missing (7.5 mg/day)
Bisoprolol, Hydrochlorothiazide, Ramipril, Trimipramine, Pantoprazole, Acetylsali-cylic acid, Ibuprofen
H53: Visual disturbances
I10: Essential (primary) hypertension
I27: Other pulmonary heart diseases
I34: Atrial fibrillation and flutter
K43: Ventral hernia
R26: Abnormalities of gait and mobility
Z93: Artificial opening status
Z96: Presence of other functional implants
E11: Type 2 diabetes mellitus
Zopiclon/120 pellets (missing)
Allopurinol, Amlodipine, Enalapril, Moxonidine
I10: Essential (primary) hypertension
I50: Heart failure
N08: Glomerular disorders in diseases classified elsewhere
N18: Chronic kidney disease
E78: Disorders of lipoprotein metabolism and other lipidaemias
Zopiclon/180 pellets (7.5 mg/day)
Allopurinol, Felodipine, Metoprolol, Olmesartan
E79: Disorders of purine and pyrimidine metabolism
F51: Nonorganic sleep disorders I10: Essential (primary) hypertension
J44: Other chronic obstructive pulmonary disease
to explain their case-related decisions of the prescription of a PIM substance and influencing factors on it for the respective case vignette,
to discuss reasons for prescription of PIM in contrast to known recommendations generally and
to assess their knowledge, usage and acceptance of recommendations in daily practice (German PRISCUS-list).
We used these real-life case vignettes to get more authentic answers by FPs and as concrete starting points for reflection of the PIM-topic in general. One patient (>65 years) with the most prescription of benzodiazepine receptor agonists (so called Z-drugs) not corresponding to recommendations of PRISCUS per each FP was selected for the respective case vignette (see Table 1).
Statistical analysis of data based on record analysis  were done using SPSS 22.0 to describe characteristics of the sample of patients > 65 years and especially of the subsample affected by PIM prescription. Screening all documented prescribed drugs, PIM were identified according to the German PRISCUS list. Differences in distributions were examined using chi2-test. T-test for unpaired samples was conducted to examine differences of means between different groups. A logistic regression was conducted to identify predictors for PIM-prescription.
The procedure of qualitative content analysis of interviews with FPs  is based on Mayring . Two researchers analyzed the interview manuscripts by using MAXQDA® software to categorize contextual factors and individual reasons for PIM prescription from FPs’ point of view. The contents of the interviews were classified inductively to indicate pertinent categories. The derived categories were discussed and consented in the research team.
All data were pseudonymously recorded and analyzed. For integrating results, interview data (e.g. reported motives of prescription) were triangulated with data based on patient records’ analysis (e.g. relative frequencies of PIM prescription).
Description of participating family physicians
Out of 33 academic teaching physicians of the Department of General Practice of TU Dresden, working in Dresden, 7 (of which 5 were female) participated in this study. The age of the participants was distributed between 43 and 61 years, and professional experiences were reported between 7 and 22 years. Out of 7 FPs, 3 worked at group practices and 4 at single practices, At the FPs’ practices, between 2 and 6 medical assistants were employed.
Of all the 7 FPs’ patients a number of 2826 met the inclusion criteria (≥2 chronic conditions and ≥ 2 related long-term medication), and 1846 patients (65.3 %) gave their consent for participation in the study. The number of participating patients per FP varied between a minimum of 120 and a maximum of 455. 55 % were females, and the age distribution was between 23 and 100 years with a mean age of 69 (±11 SD) years. 69.4 % of the patients were > 65 years old who will be in focus of following analysis.
Based on the small sample of participating FPs, the results of the study are limited regarding representativeness of FPs and patients. To check for potential biases we compared our data with results of comparable studies (external validation, see below).
Description of the sample: elderly patients
Elderly patients [n = 1241, mean age: 76 (±6 SD), females: 56.6 %] were characterized in average by 8.3 [(±3.7 SD] documented chronic diagnosis (ICD 10) that include a total of 543 different ICD-Codes (shortened to first figure).
Top Ten of documented chronic and acute diagnosis in patients > 65 years (n = 1241)
Acute upper respiratory infections
Diabetes mellitus type 2
Other disorders of urinary system
Chronic ischaemic heart disease
Abdominal and pelvic pain
Rash and other nonspecific skin eruption
Varicosis of lower extremities
Other dorsopathies, not elsewhere classified
Reaction to severe stress
long-term (current) use of anticoagulants
Other joint disorders, not elsewhere classified
Disorders of purine and pyrimidine metabolism
65.5 % of the elderly patients were given 4 and more drugs in long term medications (M: 6.3 ± 3.3 SD). The number of prescribed drugs correlated not very strongly with the number of chronic diagnosis (r = 0.34/p ≤ 0.001).
Regarding the interpretation of documented chronic diagnoses the limitation of validity based on missing or unspecific diagnoses needs to be considered. Patients’ records consist on information about chronic diagnoses documented primary for billing purposes. Although billed drugs and medical services need to be confirmed by documenting associated diagnoses, mismatches were found in our data. An exemplary analysis regarding congruence of prescriptions of thyroid medications and associated thyroid diagnosis showed insufficiently documented thyroid diagnosis in 26.8 % of patients with diagnosed or treated thyroid diseases .
Prescription of potentially inappropriate medication
Out of the 83 PIM in the German PRISCUS list (including inappropriate drugs and in some cases inadequately dosed drugs), 41 PIM were prescribed in our sample. Using the method of record analysis, our data include all of FPs’ documented drug prescriptions, incl. private prescriptions that are not covered by the statutory health insurance respectively over the counter medication. Prescriptions by specialists were only included if FP had been informed and documented it. Since our data are related to FP prescription, the real PIM-prescription in general will be underestimated.
Top Ten of the prescribed PIM in elderly patients > 65 years (n = 1241)
Total frequency (%)
Zopiclone (>3.75 mg/d)
Zolpidem (>5 mg/d)
Lorazepam (>2 mg/d)
Brotizolam (>0.125 mg/d)
A significantly higher number of female (F: 27.6 % vs. M: 19.1 %, χ 2 = 12.0/p ≤ 0.001) and very old patients (≥80 years: 31.3 % vs. < 80 years: 21.6 %, χ 2 = 11.7/p ≤ 0.001) received a PIM prescription. Patients with at least one PIM prescription were characterized by a significantly higher number of chronic diagnoses (M 9.3 ± 3.9 SD) and long-term medication (7.5 ± 3.7 SD) compared to patients without a PIM prescription (8.0 ± 3.6 SD/t-test: p ≤ 0.001 respectively 5.4 ± 3.0 SD, t-test: p ≤ 0.001).
Influencing factors on prescription of PIM
Conducting a logistic regression, we examined the influence of binary associated factors on prescription of PIM in a multivariate model. Including gender, age, documented diagnose of a mental disorder (ICD-10: F), number of diagnoses and number of long-term medication in the regression model, the strongest effect was detected for documented mental disorders (Exp(B) = 2.0/p ≤ 0.001), followed by female gender (Exp(B) = 1.6/p ≤ 0.01) and number of long-term medication (Exp(B) = 1.2/p ≤ 0.001) as predictors for the probability of a PIM prescription. Age and number of diagnoses were not predictive for PIM prescription. The three mentioned predictors explained just 14.9 % of the variance (Nagelkerkes R2 = 0.149) of the dependent variable. However, there will be other influencing variables we did not include in the model. Our findings are comparable to other studies that found depression as one of the common mental disorders in elderly patients as main predictor (OR = 2.42) for PIM prescription, followed by the number of prescribed drugs (OR = 1.99) . A positive correlation between the number of prescribed drugs and the risk of PIM in the elderly was also shown in the study of Schubert .
Knowledge and application of PRISCUS-list
Pros and Cons of the PRISCUS-list from FPs’ point of view
FPs’ arguments pro PRISCUS
FPs’ arguments contra PRISCUS
•Includes no-go-medication you have to remember every time
Not practicable in FPs’ daily practice since
•Good for orientation
•does often not fit individual patients’ needs
•Possible argument if FP wants to refuse a medication
•within its complex context of multimorbidity
•does not recommend practicable and pharmacologically based alternatives
•does not fit experience-based practice
•does not fit patient demands for a certain PIM based on individual positive experiences
•limited time in consultations a) to check additional recommendation lists and b) to convince patients for new medication
•chronological age does not match biological age: lot of patients > 65 years have a younger biological age
•mistrust in PRISCUS based on missing evidence for medication of multimorbid elderly patients
Yes, both me and my colleagues have a short version pinned up at our desks. But if you look at the list you get lost even before the consultation with the patient starts. It is not useful at all, unless you want to refuse a prescription of a medication, of course. [FP6]
The inherent problem of lack of time (the average duration of consultation at FPs’ practices is ca. 8 min per patient in Germany ) was mentioned by most of the FPs. This finding is comparable to other studies that also pointed out lack of time as a main barrier for appropriate prescribing [20, 21] or for implementing recommendations of guidelines in daily practice .
Several FPs were doubtful regarding the evidence of PRISCUS list since most of pharmacological studies exclude elderly patients, and therefore related evidence is missing. Other studies also showed partly existing skeptical attitudes of physicians regarding cited evidence in guidelines . Two FPs criticized that the PRISCUS list does not recommend “practicable and pharmacologically based alternatives” [FP6]. For instance, regarding the prescription of sedatives/hypnotics, FPs reported great uncertainty (see below).
One FP argued that primary care physicians mostly act intuition- and experience-based. From his point of view, evidence-based practice that includes implementation of guidelines in daily practice would not be typical for FPs’ practice. Triangulating these interview data with related data of patient records’ analysis, we detected that this intuition- and experience-oriented FP had a visibly lower prescription rate of PIM while reporting the highest proportion of patients > 65 years. Nevertheless, this single example might not be representative for all FPs. However, intuition-based and evidence-based acting do not exclude each other in the dichotomous way of a “zero-sum relationship” .
Social desirability was assumed in some FPs who reported knowing PRISCUS. Asked for their concrete criticisms they first reported weakness of PRISCUS list in general, and, after repeating the question, they apologized for not remembering since they do not use the list. There were two FPs knowing nothing of PRISCUS and PIM at all. This is similar to results of other studies describing educational lacks in primary care as well as hospital physicians, regarding appropriate prescribing in elderly patients [20, 21].
Reported causes for prescription of potentially inappropriate medication
Regarding polypharmacy, there are no convincing recommendations as to what to prescribe as an alternative. Full stop. That is why I consult these patients (note: with PIM) closely. I will see them several times in the quarter at my practice to keep a close eye on them. [FP2]
(Note: As with PIM) you have similar issues with these huge amounts of pain pellets or patients receiving Falithrom (note: Phenprocoumon). Every time something can happen. But this is unavoidable, isn’t it? [FP5]
If you keep the wellbeing of the patient as the primary goal in mind, then a lot will be sorted based on this prioritization. Age seems to be a difficult criterion in general, so patients’ health status and perspectives should be more important. [FP2]
Regarding sedatives, benzodiazepine vs. z-drugs it is like being caught between a rock and a hard place. I am certain that it (note: PIM) is not recommended by PRISCUS but there are no alternatives. And the patient needs to get sleep and be pain-free from time to time. So we talk to the patient about the medication, how to limit it time-wise and how to monitor it closely. [FP1]
You can start making changes in medication, yes, but most of them are not successful. [FP1]
Well, you can speak like a priest in the church: if patients have a certain level of addiction it is really difficult. I could refuse them the medication, but then they will go to a different [physician], so this doesn’t make any sense. [FP7]
This finding is convenient to our previous result of the logistic regression (see above), showing that a documented mental disorder was the strongest predictor for prescription of PIM.
I had special cases of patients, when I said, okay, let’s keep them in “one hand” and see if we can somehow take responsibility for it. Yes, we try to care for them individually. Last time I had a patient, she picked up sleeping pills from her neurologist, from me and from another GP. And then at night she had a bad fall because she was just completely in the swash. Finally she was hospitalized, but how to manage her? I have no magic remedy for this problem. [FP4]
Most of the FPs described the importance of close cooperation with neurologists/psychiatrists regarding care for patients addicted to hypnotics, but several problems were pointed out. First, they reported patients’ difficulties to get access to a psychiatrist for “just” sleeping disorders and second, they reported communication lacks regarding prescriptions of medications and lacks in referral of clinical information. And third, some of the FPs pointed out an uncritical prescribing by psychiatrists without looking at the patient in their entirety including existing multimorbidity. But especially in the case of out-patient detoxification, FPs underlined the necessity of cooperation. To summarize, most of the FPs saw great challenges and chances in a better cooperation with psychiatrists to improve medical care for (elderly) patients addicted to hypnotics.
patient-oriented prioritization reflecting i.e. multimorbidity and related polypharmacy, existing mental disorders, gender, patients’ requests  and experiences
FPs’ knowledge regarding e.g. existing evidence/recommendations and their trust in it
dependent on quality of cooperation with in- and out-patient specialist; forwarded information regarding clinical indication and prescribed drugs
organizational characteristics, i.e. lack of time in daily practice, follow-up prescriptions of PIM initially prescribed by specialists.
Obviously, there is a problem with the applicability of guidelines and recommendations, rooted in the special characteristics of FPs´ work: the individual consideration of decisions against the background of the knowledge of the patient’s medical history, patient´s characteristics and suspected adherence.
Partly, FPs reported to be not really convinced of their decisions foreseeing associated higher risks of drug related adverse events. Assuming that they will not find medication alternatives for individual multimorbid patients, frequently re-consultations and laboratory tests were seen as methods to detect drug related problems as soon as possible.
The partly detected education lack regarding PIM and PRISCUS shows challenges for further educational tasks that should take the partly missing trust in recommendation and PRISCUS into account even though influence of new guidelines and their recommendations on physicians’ daily practice seems to be limited .
FP, family practitioner; PIM, potentially inappropriate medication; PRISCUS, PRerequISites for a new health Care model for elderly people with mUltiple morbiditieS
We thank Roland-Ernst Foundation that granted the whole project. We also thank the participating FPs and their medical assistants who enabled data collection and were willing to be interview partners. We thank our project assistant Grit Hübsch and our student assistant Nadine Gunder who did a great job in collecting the data. Finally we thank our language editor Gerit Rother for revising our manuscript.
This project was funded by Roland-Ernst Foundation who had no influence in the design of the study, collection, analysis, and interpretation of data, and in writing the manuscript.
Availability of data and materials
According to the ethical requirements in our ethics approval, the recorded pseudonymized data are stored at the Department of General Practice at Technische Universität Dresden. Following German data protection laws, only authorized persons have access to the data. Requests for more detailed information regarding instruments can be addressed to the corresponding author.
KV, MG, JKN, AB, JS made substantial contributions to conception and design of the study. Data collection was coordinated by MG, KV and supported by NQ. Data analysis and interpretation was done by NQ, KV, MG. The manuscript was drafted by KV, MG, JKN, AB. JS and NQ revised critically the manuscript. All mentioned authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Ethical consent was confirmed by the Ethical Commission of the Faculty of Medicine at the Technische Universität Dresden (EK410122012). Following the common ethical requirements, all participants (FP, patients, medical assistants) of the study gave their written consent to participate in our study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Beers E, Moerkerken DC, Leufkens HG, Egberts TC, Jansen PA. Participation of older people in preauthorization trials of recently approved medicines. J Am Geriatr Soc. 2014;62(10):1883–90.View ArticlePubMedGoogle Scholar
- Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G, Clarfield AM, Crome P, Hertogh C, Lesauskaite V, Prada GI, Szczerbinska K, Topinkova E, Sinclair-Cohen J, Edbrooke D, Mills GH. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171(6):550–6.View ArticlePubMedGoogle Scholar
- Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107–16.View ArticlePubMedGoogle Scholar
- Gurwitz JH, Field TS, Judge J, Rochon P, Harrold LR, Cadoret C, Lee M, White K, LaPrino J, Erramuspe-Mainard J, DeFlorio M, Gavendo L, Auger J, Bates DW. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med. 2005;118(3):251–8.View ArticlePubMedGoogle Scholar
- Reich O, Rosemann T, Rapold R, Blozik E, Senn O. Potentially inappropriate medication use in older patients in Swiss managed care plans: prevalence, determinants and association with hospitalization. PLoS One. 2014;9(8):e105425.View ArticlePubMedPubMed CentralGoogle Scholar
- Fialova D, Topinkova E, Gambassi G, Finne-Soveri H, Jonsson PV, Carpenter I, Schroll M, Onder G, Sorbye LW, Wagner C, Reissigova J, Bernabei R. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA. 2005;293(11):1348–58.View ArticlePubMedGoogle Scholar
- Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An Update Arch Intern Med. 1997;157(14):1531–6.View ArticlePubMedGoogle Scholar
- Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716–24.View ArticlePubMedGoogle Scholar
- Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.View ArticlePubMedGoogle Scholar
- Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011;171(11):1013–9.View ArticlePubMedGoogle Scholar
- Laroche ML, Charmes JP, Merle L. Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin Pharmacol. 2007;63(8):725–31.View ArticlePubMedGoogle Scholar
- Mann E, Böhmdorfer B, Frühwald T, Roller-Wirnsberger RE, Dovjak P, Dückelmann-Hofer C, Fischer P, Rabady S, Iglseder B. Potentially inappropriate medication in geriatric patients: the Austrian consensus panel list. Wien Klin Wochenschr. 2012;124(5–6):160–9.View ArticlePubMedGoogle Scholar
- Rognstad S, Brekke M, Fetveit A, Spigset O, Wyller TB. Straand J+. The Norwegian General Practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients: a modified Delphi study. Scand J Prim Health Care. 2009;27(3):153–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Holt S, Schmiedl S, Th++rmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Deutsches Ärzteblatt Int. 2010;107(31–32):543.Google Scholar
- Opondo D, Eslami S, Visscher S, De Rooij SE, Verheij R, Korevaar JC, Abu-Hanna A. Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review. PLoS One. 2012;7(8):e43617.View ArticlePubMedPubMed CentralGoogle Scholar
- Fiss T, Thyrian JR, Fendrich K, Berg N, Hoffmann W. Cognitive impairment in primary ambulatory health care: pharmacotherapy and the use of potentially inappropriate medicine. Int J Geriatric Psychiatry. 2013;28(2):173–81.View ArticleGoogle Scholar
- Zimmermann T, Kaduszkiewicz H, van den Bussche H, Schön G, Brettschneider C, König HH, Wiese B, Bickel H, Mösch E, Luppa M, et al. Potentially inappropriate medication in elderly primary care patients. A retrospective, longitudinal analysis. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz. 2013;56(7):941–9.View ArticlePubMedGoogle Scholar
- Schubert I, Küpper-Nybelen J, Ihle P, Thürmann P. Prescribing potentially inappropriate medication (PIM) in Germany’s elderly as indicated by the PRISCUS list. An analysis based on regional claims data. Pharmacoepidemiol Drug Saf. 2013;22(7):719–27.View ArticlePubMedGoogle Scholar
- Maio V, Jutkowitz E, Herrera K, Abouzaid S, Negri G, Del Canale S. Appropriate medication prescribing in elderly patients: how knowledgeable are primary care physicians? A survey study in Parma, Italy. J Clin Pharm Ther. 2011;36(4):468–80.View ArticlePubMedGoogle Scholar
- Ramaswamy R, Maio V, Diamond JJ, Talati AR, Hartmann CW, Arenson C, Roehl B. Potentially inappropriate prescribing in elderly: assessing doctor knowledge, confidence and barriers. J Eval Clin Pract. 2011;17(6):1153–9.View ArticlePubMedGoogle Scholar
- Hübsch G, Gottschall M, Mergenthal K, Schübel J, Bergmann A, Voigt K. Are Saxonian Family Practices on the Way to Team Practices? ZFA. 2015;91(6):264–8.Google Scholar
- Creswell JW, Fetters MD, Ivankova NV. Designing a mixed methods study in primary care. Ann Fam Med. 2004;2(1):7–12.View ArticlePubMedPubMed CentralGoogle Scholar
- Köberlein J, Gottschall M, Czarnecki K, Thomas A, Bergmann A, Voigt K. General practitioners’ views on polypharmacy and its consequences for patient health care. BMC Fam Pract. 2013;14:119.View ArticlePubMedPubMed CentralGoogle Scholar
- Mayring P. Qualitative Inhaltsanalyse. Weinheim und Basel: Beltz-Verlag; 2010.View ArticleGoogle Scholar
- Münch C. Quality of documentation of diagnoses by GPs with an example of thyroid diseases [Master Thesis at Technische Universität Dresden/Faculty of Medicine] 2015Google Scholar
- Van den Brink-Muinen A, Verhaak PF, Bensing JM, Bahrs O, Deveugele M, Gask L, Mead N, Leiva-Fernandez F, Perez A, Messerli V. Communication in general practice: differences between European countries. Fam Pract. 2003;20(4):478–85.View ArticlePubMedGoogle Scholar
- Kastner M, Estey E, Hayden L, Chatterjee A, Grudniewicz A, Graham ID, Bhattacharyya O. The development of a guideline implementability tool (GUIDE-IT): a qualitative study of family physician perspectives. BMC Fam Pract. 2014;15:19.View ArticlePubMedPubMed CentralGoogle Scholar
- Wollny A, Rieger MA, Wilm S. Inadequate reimbursement and the patients themselves may inhibit the implementation of guidelines. Evaluation of the venous leg ulcer guideline of the German Society of Phlebology (DGP) in general and phlebology practices. Z Evid Fortbild Qual Gesundhwes. 2009;103(7):431–7.View ArticlePubMedGoogle Scholar
- Greenhalgh T. Intuition and evidence--uneasy bedfellows? Br J Gen Pract. 2002;52(478):395–400.PubMedPubMed CentralGoogle Scholar
- Schubert I, Egen-Lappe V, Heymans L, Ihle P, Feßler J. ‘To Read’ does not Imply ‘To Act upon’: Indicators of the Acceptance of General Practice Guidelines. Results of a Survey among Quality Circles of General Practitioner Centred Care (Hausarztzentrierte Versorgung; HZV). Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 2009;103(1):5–12.View ArticlePubMedGoogle Scholar